Cysteinyl leukotrienes are autocrine and paracrine regulators of fibrocyte function

Journal of Immunology

Volumn 179, Issue 11, 2007, Pages 7883-7890

  Vannella, Kevin M ^a   McMillan, Tracy R ^b   Charbeneau, Ryan P ^b   Wilke, Carol A ^b   Thomas, Peedikayil E ^b   Toews, Galen B ^b   Peters Golden, Marc ^b   Moore, Bethany B ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FLUORESCEIN ISOTHIOCYANATE; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR; PEPTIDOLEUKOTRIENE; TOMELUKAST; VERLUKAST; ARACHIDONATE 5 LIPOXYGENASE; CYSTEINE; CYSTEINYL LEUKOTRIENE RECEPTOR 2; CYSTEINYL-LEUKOTRIENE; LEUKOTRIENE; LEUKOTRIENE D4 RECEPTOR; MEMBRANE PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; FIBROBLAST; LUNG FIBROSIS; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; ANIMAL; AUTOCRINE EFFECT; C57BL MOUSE; CHEMOTAXIS; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; MESENCHYMAL STEM CELL; METABOLISM; MOUSE MUTANT; PARACRINE SIGNALING; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; AUTOCRINE COMMUNICATION; CELL PROLIFERATION; CHEMOTAXIS; CYSTEINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; LEUKOTRIENES; MEMBRANE PROTEINS; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PARACRINE COMMUNICATION; PULMONARY FIBROSIS; RECEPTORS, LEUKOTRIENE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38849161533     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.11.7883     Document Type: Article

References (41)

1. Kuhn, C. 1995. Pathology. In Pulmonary Fibrosis. S. Phan and R. Thrall, eds. Dekker, New York, pp. 59-83.
2. Gottleib, D. J., and G. L. Snider. 1995. Lung function in pulmonary fibrosis. In Pulmonary Fibrosis. S. Phan and R. Thrall, eds. Dekker, New York, p. 85.
3. Abe, R., S. C. Donnelly, T. Peng, R. Bucala, and C. N. Metz. 2001. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166: 7556-7562.
4. Bucala, R., L. A. Spiegel, J. Chesney, M. Hogan, and A. Cerami. 1994. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1: 71-81.
5. Chesney, J., and R. Bucala. 2000. Peripheral blood fibrocytes: mesenchymal precursor cells and the pathogenesis of fibrosis. Curr. Rheumatol. Rep. 2: 501-505.
6. Moore, B. B., J. E. Kolodsick, V. J. Thannickal, K. Cooke, T. A. Moore, C. Hogaboam, C. A. Wilke, and G. B. Toews. 2005. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol. 166: 675-684.
7. Phillips, R. J., M. D. Burdick, K. Hong, M. A. Lutz, L. A. Murray, Y. Y. Xue, J. A. Belperio, M. P. Keane, and R. M. Strieter. 2004. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 114: 438-446.
8. Schmidt, M., G. Sun, M. Stacey, L. Mori, and S. Mattoli. 2003. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J. Immunol. 170: 380-389.
9. Chesney, J., C. Metz, A. B. Stavitsky, M. Bacher, and R. Bucala. 1998. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J. Immunol. 160: 419-425.
10. Ozaki, O., H. Hayashi, K. Tani, F. Ogushi, U. Yasuoka, and T. Ogura. 1992. Neutrophil chemotactic factor in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 145: 85-91.
11. 4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J. Allergy Clin. Immunol. 84: 19-26.
12. Wilborn, J., M. Bailie, M. Coffey, M. Burdick, R. Strieter, and M. Peters-Golden. 1996. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest. 97: 1827-1836.
13. Bitterman, P., N. Wewers, S. Rennard, S. Adelberg, and R. Cyrstal. 1986. Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators. J. Clin. Invest. 77: 700-708.
14. Elias, J., M. Rossman, R. Zurier, and R. Daniele. 1985. Human alveolar macrophage inhibition of lung fibroblast growth: a prostaglandin-dependent process. Am. Rev. Respir. Dis. 131: 94-99.
15. Korn, J., P. Halushka, and E. Leroy. 1980. Mononuclear cell modulation of connective tissue function: suppression of fibroblast growth by stimulation of endogenous prostaglandin production. J. Clin. Invest. 65: 543-554.
16. 2 and to express cyclooxygenase-2. J. Clin. Invest. 95: 1861-1868.
17. Peters-Golden, M., M. Bailie, T. Marshall, C. Wilke, S. H. Phan, G. Toews, and B. Moore. 2002. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. 165: 229-235.
18. Failla, M., T. Genovese, E. Mazzon, E. Gili, C. Muia, M. Sortino, N. Crimi, A. P. Caputi, S. Cuzzocrea, and C. Vancheri. 2006. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir. Res. 7: 137.
19. Izumo, T., M. Kondo, and A. Nagai. 2007. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice. Life Sci. 80: 1882-1886.
20. Mensing, H., and B. Czarnetzki. 1984. Leukotriene B4 induces in vitro fibroblast chemotaxis. J. Invest. Dermatol. 82: 9-12.
21. Baud, L., J. Perez, M. Denis, and R. Ardaillou. 1987. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J. Immunol. 138: 1190-1195.
22. 4 to rat lung fibroblasts and stimulation of collagen synthesis in vitro. Biochemistry 27: 2846-2853.
23. Chen, X. S., J. R. Sheller, E. N. Johnson, and C. D. Funk. 1994. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372: 179-182.
24. Moore, B. B., R. Paine, III, P. J. Christensen, T. A. Moore, S. Sitterding, R. Ngan, C. A. Wilke, W. A. Kuziel, and G. B. Toews. 2001. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J. Immunol. 167: 4368-4377.
25. Thomas, P. E., M. Peters-Golden, E. S. White, V. J. Thannickal, and B. B. Moore. 2007. PGE2 inhibition of TGF-β1-induced myofibroblast differentiation is Smad-independent but involves cell shape and adhesion-dependent signaling. Am. J. Physiol. 293: L417-L428.
26. Fink, L., W. Seeger, L. Ermert, J. Hanze, U. Stahl, F. Grimminger, W. Kummer, and R. M. Bohle. 1998. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat. Med. 4: 1329-1333.
27. + T-cells during a pulmonary cryptococcus-neoformans infection. J. Immunol. 155: 4790-4797.
28. Petersgolden, M., and P. Thebert. 1987. Inhibition by methylprednisolone of zymosan-induced leukotriene synthesis in alveolar macrophages. Am. Rev. Respir. Dis. 135: 1020-1026.
29. Evans, J. F. 2002. Cysteinyl leukotriene receptors. Prostaglandins Other Lipid Mediat. 68-69: 587-597.
30. Moore, B. B., L. Murray, A. Das, C. A. Wilke, A. B. Herrygers, and G. B. Toews. 2006. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am. J. Respir. Cell Mol. Biol. 35: 175-181.
31. Mehrad, B., M. Burdick, D. Zisman, P. Keane, J. Belpario, and R. Strieter. 2007. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem. Biophys. Res. Commun. 353: 104-108.
32. 2- adrenergic agonists. Am. J. Physiol. 283: L1033-L1042.
33. James, A. J., J. F. Penrose, A. M. Cazaly, S. T. Holgate, and A. P. Sampson. 2006. Human bronchial fibroblasts express the 5-lipoxygenase pathway. Respir. Res. 7: 102.
34. 4. Infect. Immun. 61: 671-679.
35. Zeiher, B. G., S. Matsuoka, K. Kawabata, and J. E. Repine. 2002. Neutrophil elastase and acute lung injury: prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics. Crit. Care Med. 30: S281-S287.
36. Shen, H., S. Paul, L. M. Breuninger, P. J. Ciaccio, N. M. Laing, M. Helt, K. D. Tew, and G. D. Kruh. 1996. Cellular and in vitro transport of glutathione conjugates by MRP. Biochemistry 35: 5719-5725.
37. Downie, M. M., D. A. Sanders, L. M. Maier, D. M. Stock, and T. Kealey. 2004. Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro. Br. J. Dermatol. 151: 766-775.
38. Yamakawa, K., M. Hosoi, H. Koyama, S. Tanaka, S. Fukumoto, H. Morii, and Y. Nishizawa. 2000. Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 271: 571-574.
39. 2 in bleomycin-induced pulmonary fibrosis. Nat. Med. 8: 480-484.
40. Beller, T. C., D. S. Friend, A. Maekawa, B. K. Lam, K. F. Austen, and Y. Kanaoka. 2004. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc. Natl. Acad. Sci. USA 101: 3047-3052.
41. Beller, T. C., A. Maekawa, D. S. Friend, K. F. Austen, and Y. Kanaoka. 2004. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J. Biol. Chem. 279: 46129-46134.